O-GlcNAcylated FTO promotes m6A modification of SOX4 to enhance MDS/AML cell proliferation

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Fat mass and obesity-associated protein (FTO) is a key m6A demethylase.
• The role and functional implications of FTO O-GlcNAcylation are not well understood.
• O-GlcNAcylation is a common post-translational modification of nuclear and cytosolic proteins.

Purpose of the Study:

• To investigate the O-GlcNAcylation of FTO.
• To elucidate the functional consequences of FTO O-GlcNAcylation in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).
• To explore FTO O-GlcNAcylation as a potential therapeutic target for MDS/AML.

Main Methods:

• Correlation analysis of FTO expression and O-GlcNAcylation in MDS/AML patients.
• Assessment of m6A modification levels of SOX4.
• Evaluation of cell apoptosis and proliferation.
• In vitro inhibition of FTO O-GlcNAcylation and its effect on AML progression.

Main Results:

• A negative correlation was observed between FTO expression and O-GlcNAcylation in MDS/AML patients.
• Decreased FTO O-GlcNAcylation led to reduced m6A modification of SOX4, promoting apoptosis and inhibiting proliferation.
• FTO O-GlcNAcylation stabilized SOX4 transcripts, increasing AKT/MAPK phosphorylation and decreasing apoptosis.
• Inhibition of FTO O-GlcNAcylation slowed AML progression in vitro, consistent with clinical data.

Conclusions:

• FTO O-GlcNAcylation plays a critical role in RNA m6A methylation.
• FTO O-GlcNAcylation influences the progression of MDS and AML.
• Targeting FTO O-GlcNAcylation presents a potential therapeutic strategy for MDS/AML.